The global healthcare economic burden, at present, is primarily characterized by major contributors such as chronic pain and neurological disorders. The annual societal cost for chronic pain and neurological disorders accounted for $635 billion and $789 billion respectively in the U.S., in 2014. Opioids are one of the most preferred medicines for the treatment of chronic pain, however, the side-effects associated with opioids have resulted in a decline in their overall usage and sale. Consequently, the increasing cases of neurological disorders and the need for a novel approach for the treatment of such diseases has led to the advent of neuromodulation technologies. The rapid shift of the healthcare industry toward neurostimulation devices from opioids and other conventional treatment techniques can be attributed to the efficient, safe, and targeted approach of neurostimulation devices. BIS Research recently published a market intelligence report titled “ Global Neurostim